102 results about "Ovarian function" patented technology

The invention discloses application of an ACSL4 inhibitor in preparation of a medicine for improving quality reduction of an elderly ovum, and belongs to the technical field of biological medicines. The invention provides an application of targeting long-chain fatty acid acyl-coenzyme A synthetase 4 (ACSL4) in intervention of low oocyte quality and related fertility decline caused by aging. The ACSL4 inhibitor can be used for preparing drugs for improving ovarian functions and improving oocyte quality. In-vivo and in-vitro experiments prove that by inhibiting the ACSL4, the aging process of the elderly ovary can be effectively relieved, the expression of aging-related proteins p16 and p21 can be reduced, the mitochondrial function of the oocyte can be improved, and spindle assembly abnormality and chromosome arrangement defects can be rescued, so that the maturation rate and the development potential of the oocyte can be remarkably improved.

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The present application relates to the field of biological medicine and modernization of traditional Chinese medicine, and particularly relates to a therapeutic target, an inhibitor and a traditional Chinese medicine composition for treating ovarian hypofunction caused by oxidative stress and application thereof. The present application first determines SRC tyrosine kinase as a key drug target for preventing and treating the disease. The application of the SRC tyrosine kinase inhibitor (such as secaitinib) in preparing related drugs is provided, which can alleviate the damage of ovarian granulosa cells by inhibiting the SRC activity, down-regulating the expression of antioxidant enzyme related genes and reducing the level of active oxygen. Meanwhile, the present application provides a traditional Chinese medicine composition composed of mulberry, kudzu root, tuckahoe and medlar. The composition can improve the hormone level, enhance the antioxidant capacity, improve the ovarian function and fertility by inhibiting the SRC tyrosine kinase activity and the SRC-RAF1-MEK-ERK signal pathway. The present application provides a new solution for the targeted treatment of ovarian hypofunction and the modernization of traditional Chinese medicine.

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

Provided are a biological material for restoring ovarian functions, a preparation method therefor and the use thereof, relating to the technical field of biological materials. A large number of experiments verify that: it is found that a specific biological protein component for reversing ovarian functions in extracellular vesicles is the growth differentiation factor 9 (GDF-9), and the mechanism of action thereof for restoring the ovary is determined, and therefore extracellular vesicles (GOEs) that overexpress GDF-9 serve as an active substance, and by means of extraction and purification of said component, the purpose of targeted therapy is achieved.

This invention discloses an AI-based personalized dynamic embryo culture system, belonging to the field of embryo culture technology. The system adopts a modular architecture, including a core control module, at least one independent culture chamber module, an AI analysis module, and a dynamic regulation module. By employing microfluidic chip technology and an integrated microsensor array, this invention achieves high-precision real-time monitoring of embryo morphology images and physiological parameters of the culture medium. Combined with multimodal data fusion analysis using the AI ​​analysis module, it significantly improves the accuracy and reliability of embryo developmental potential assessment, thereby contributing to increased rates of high-quality embryos and clinical pregnancy success. Furthermore, this invention, through a built-in personalized protocol generation unit, can dynamically generate and execute personalized culture protocols based on the patient's age, ovarian function indicators, and basal hormone levels, while utilizing the dynamic regulation module to simulate the uterine diurnal rhythm for temperature fluctuation control.

The invention provides a Chinese herbal medicine leavening agent for improving the egg laying performance of hens in the later egg laying period as well as a preparation method and application of the Chinese herbal medicine leavening agent. The Chinese herbal medicine leavening agent is obtained by fermenting compound Chinese herbal medicines including motherwort, angelica sinensis, ligusticum wallichii, peach kernels, astragalus membranaceus and baked ginger with compound probiotics, namely bacillus subtilis, saccharomyces cerevisiae and lactobacillus plantarum. The compound probiotics are adopted for solid-state fermentation of the compound Chinese herbal medicine, strain compatibility is reasonable, the process is simple and efficient, synergistic fermentation is achieved, and release of active ingredients of the Chinese herbal medicine can be effectively promoted; the Chinese herbal medicine leavening agent is added into hen feed in the later egg laying period in proportion, the fat metabolism of hens can be adjusted, the content of intestinal digestive enzymes and reproductive hormone can be increased, the ovarian function of laying hens can be improved, the egg laying performance and the egg quality can be improved, and the Chinese herbal medicine leavening agent has good application prospects.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an SIRT5 inhibitor MC3482 in preparation of a medicine for treating premature ovarian failure. According to the invention, a mouse POI model is constructed through the induction of cyclophosphamide (CTX), and the MC3482 is proved to be capable of inhibiting the activity of SIRT5, reducing excessive macrophage infiltration of ovary caused by CTX, reducing M1 type macrophage activation and proinflammatory factor release, further inhibiting the apoptosis of ovarian granular cells, protecting follicular reserve and recovering ovarian functions. The invention clarifies the action effect and application scheme of MC3482 for preventing and treating POI, provides a new treatment strategy for chemotherapy-induced iatrogenic POI, and has important clinical transformation value.

This application relates to the field of medical data processing technology and discloses a method and system for screening infertile patients with polycystic ovary syndrome (PCOS). The method includes: acquiring data on the number of antral follicles, anti-Müllerian hormone (AMH) concentration, and ovarian volume from multiple patient monitoring cycles; performing feature extraction and normalization to obtain a set of normalized feature vectors; determining the synchronous relationship between the number of antral follicles and ovarian volume based on the vector set, and identifying signs of asynchronous changes; combining hormone concentrations for joint grouping to obtain the distribution of abnormal indicator clusters and identifying ovarian function stage markers; performing sequence matching based on the stage markers of continuous cycles and historical medical records to generate an ovarian function progression trajectory curve; extracting inflection point features from the curve and performing causal association rule mining to construct a logical chain between abnormal indicators and clinical outcomes; and determining conditions layer by layer according to the logical chain to output the final screening results. This application improves the accuracy of screening infertile patients with PCOS.

The invention discloses a stem cell exosome composition for improving premature ovarian failure as well as a preparation method and application of the stem cell exosome composition. The composition is composed of human umbilical cord mesenchymal stem cell exosomes obtained through hypoxia and TGF-beta1 combined pretreatment and resveratrol, and the human umbilical cord mesenchymal stem cell exosomes and the resveratrol are compounded according to a specific mass ratio. The pre-treatment condition is that 1% oxygen concentration and 10 ng / ml TGF-beta1 are co-cultured for 48 hours, and the condition can synergistically up-regulate the expression level of specific miRNA in the exosome. The composition prepared through physical incubation and an ultrafiltration method shows a clear synergistic treatment effect in vitro and in vivo, the combination index of the composition is 0.38-0.45, ovarian endocrine indexes can be effectively recovered, follicular reserve can be protected, and oxidative stress and inflammation states of ovarian tissues can be remarkably improved. The invention provides a novel treatment strategy with a novel mechanism and a remarkable curative effect for premature ovarian failure, especially chemotherapy-induced ovarian function impairment.

The invention provides a transdermal absorption composition containing six active peptides and application of the transdermal absorption composition. The transdermal absorption composition is prepared from 0.5 to 5 parts of acetyl hexapeptide-8, 0.5 to 5 parts of decapeptide-4, 0.5 to 5 parts of oligopeptide-1, 1 to 10 parts of glycoprotein, 1 to 8 parts of serum protein, 5 to 20 parts of soluble collagen, 3 to 12 parts of mannitol, 2 to 10 parts of trehalose, 1 to 5 parts of caprylyl glycol and 5 to 25 parts of butanediol. The composition is used for preparing transdermal absorption products for improving ovarian functions and delaying ovarian aging. Through a penetration enhancer combination and raw material modification process, the technical problems that polypeptide is difficult to transdermal and easy to inactivate are effectively solved, and the skin permeability and stability of active ingredients are improved, so that the ovarian function is improved through synergistic interaction.

The invention belongs to the technical field of biological medicine manufacturing, and particularly relates to a pharmaceutical preparation for improving ovarian functions and a preparation method thereof. The pharmaceutical preparation comprises the following raw materials in parts by weight: 12-25 parts of berberine hydrochloride, 8-16 parts of shionone, 5-10 parts of dicliptera chinensis polysaccharide, 10-20 parts of a diluent, 5-9 parts of an adhesive and 1-6 parts of a lubricant. According to the pharmaceutical composition, berberine hydrochloride, shionone and dicliptera chinensis polysaccharide are compounded, sexual cycle disorder caused by the polycystic ovarian syndrome is adjusted in a synergistic interaction mode, insulin resistance is improved, indexes such as luteinizing hormone (LH), follicle-stimulating hormone (FSH) and LH / FSH are remarkably improved, and the pharmaceutical composition has the application potential of treating the polycystic ovarian syndrome and has good application prospects. And the market prospect is wide.

The invention provides an application of an E3 ubiquitin ligase RLIM gene inhibitor in preparation of a medicine for treating ovarian aging or injury. Experiments find that the expression level of the RLIM gene in the ovary is positively correlated with the aging degree, and the expression of the RLIM gene is remarkably improved along with age increase. In-vivo and in-vitro experiments show that ovarian granular cell senescence can be effectively delayed and ovarian functions can be improved by inhibiting RLIM expression, and particularly, the proportion of atresia follicles is reduced, the number of healthy follicles is increased, and serum AMH and E2 levels are remarkably improved. The pharmaceutical composition provided by the invention comprises a siRNA inhibitor (preferably, siRLIM-2) of specific targeting RLIM and a nano-liposome carrier, and efficient targeting delivery can be realized through tail vein injection. The treatment scheme has no toxic effect on important organs, is high in safety, and provides a new effective means for treatment of ovarian aging and related diseases.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating polycystic ovarian syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from Chinese yam, semen cuscutae, pulp of dogwood fruit, radix glehniae, radix scrophulariae, lily, rhizoma polygonati, tortoise shell, cistanche deserticola, lotus seed and raspberry, has the effects of tonifying kidney and replenishing essence, nourishing yin and blood, replenishing qi and tonifying spleen, and benefiting uterus and accommodating fetus, and is mainly used for treating the polycystic ovarian syndrome. Research results show that the traditional Chinese medicine composition can significantly improve the sex hormone level of a patient with the polycystic ovarian syndrome, increase the endometrial thickness, improve the ovarian function and improve the endometrial receptivity, the ovulation rate and the pregnancy rate. Therefore, the traditional Chinese medicine composition has important clinical significance and wide market application prospects.

The present application relates to the technical field of biological medicine, in particular to a diplommatin composition for regulating ovary function and improving menopausal syndrome, a preparation method and application thereof, active ingredients of the composition include diplommatin and cranberry extract by mass fraction, and the mass ratio of diplommatin to cranberry extract is 1:(0.5-5), or active ingredients of the composition are composed of diplommatin, cranberry extract and carob extract according to a mass ratio of 1:(0.5-5):(0.5-5). The composition has a simple component design, effectively solves the problems of "complex components, unknown mechanism, low bioavailability and poor long-term safety" in the prior art through multi-component synergy, and precisely regulates ovary function and systematically improves menopausal syndrome related symptoms.

The invention relates to the technical field of biological medicines, and particularly discloses application of formononin in preparation of a medicine for regulating and controlling BNIP3-mediated excessive mitochondrial autophagy. The invention discloses that ononin can be used as a direct small molecule inhibitor of BNIP3 protein, specific binding of ononin with BNIP3 is verified through molecular docking, surface plasmon resonance and molecular dynamics simulation in multiple dimensions, and in an iron overload induced ovarian granulosa cell injury model, the ononin can be used as an iron overload induced ovarian granulosa cell injury model. The formononin effectively inhibits mitochondrial excessive autophagy mediated by a BNIP3-PINK1 / Parkin axis through targeting BNIP3, remarkably recovers mitochondrial membrane potential, reduces mitochondrial active oxygen level and improves cell oxygen consumption rate (OCR), so that stressful high-flux and low-efficiency breathing states are corrected, cell senescence phenotypes are delayed, and cell apoptosis is inhibited. And a new small molecule drug strategy with a clear structure and a clear action mechanism is provided for iron overload related ovarian function impairment.

This invention provides a method to improve age-related decline in ovarian function by supplementing quiescent oocytes within primordial follicles. [Solution] The present invention provides a method for inducing mature oocytes, comprising the steps of: preparing a single-cell suspension from the ovary of a mammal other than a human; separating the single-cell suspension into oocytes and ovarian somatic cells (supporting cells) within a primordial follicle using a flow cytometer; re-aggregating the oocytes and ovarian somatic cells within the separated primordial follicle; and maturing the re-aggregated primordial follicle in vitro.

The application discloses an application of pazopanib hydrochloride in preparation of an ovary function protection drug and belongs to the technical field of biological medicines. The application first discovers that pazopanib hydrochloride has good potential in preventing chemotherapy drug-induced ovary damage, and the "old drug new use" strategy can greatly shorten the research and development cost and risk. The application explores the protection effect and safety of pazopanib hydrochloride in ovary damage induced by different drugs, and provides an experimental basis and intervention means for fertility protection of female tumor patients.

The invention belongs to the technical field of biological medicine, and particularly relates to application of irisin in treatment of polycystic ovarian syndrome, and the specific application of irisin in treatment of polycystic ovarian syndrome is as follows: improving the ovarian morphology and ovarian dysfunction of a patient suffering from PCOS (polycystic ovarian syndrome); the ovarian ferroptosis and iron autophagy of the PCOS patient are improved; ferroptosis of primary ovarian granular cells and KGN cells induced by high androgen is improved; iris is used for regulating and controlling an NCOA4-FTH pathway to reverse iron autophagy of ovarian granulosa cells, and through a PCOS mouse model induced by hyperandrogen, specific targets of irisin for inhibiting ferroptosis of the ovarian granulosa cells are disclosed, abnormal iron metabolism of PCOS patients is reversed, and the normal ovulation function of the PCOS patients is recovered; a safe alternative is provided: irisin can be generated endogenously by movement, avoiding the risk of metabolic disorder caused by exogenous hormone therapy.

This invention relates to the pharmaceutical field, specifically disclosing a pharmaceutical composition and its application. The composition comprises sibifluin, uridine, and adenosine, wherein the mass ratio of sibifluin:uridine:adenosine is 6.0-11.5:0.8-1.4:1.0. This pharmaceutical composition exhibits good safety and anti-inflammatory effects, demonstrates good efficacy in the treatment of phenylketonuria, and also shows good preventative and / or therapeutic effects against ovarian insufficiency.

The invention relates to an application of an HK1 gene in mouse ovarian granular cells, in particular to an application in regulating proliferation and apoptosis of the mouse ovarian granular cells and / or steroid hormone synthesis. According to the invention, mouse ovarian granular cells are taken as a research object, and the expression of the HK1 gene is interfered to verify that the HK1 gene is taken as a key target spot for regulating and controlling the functions of the mouse ovarian granular cells so as to influence steroid hormone synthesis and cell proliferation and apoptosis processes. The invention not only provides more reliable technical support for ovarian function regulation, but also provides new thinking and technical guidance for mechanism research of reproductive diseases and preparation and development of related drugs.

The invention discloses an ovary and gonad axis function repairing preparation and a preparation process thereof, and relates to the technical field of biology, the preparation comprises the following components by weight: 22-38 parts of a marine organism polysaccharide composite raw material; 12-28 parts of a plant stem cell extract; 4 to 10 parts of deep sea sponge terpenoids; 3-7 parts of coral polysaccharide; 0.008 to 0.018 part of vitamin C palmitate; 0.4 to 0.6 part of xanthan gum; the marine organism polysaccharide composite raw material consists of fucoidan and fucoidan in a weight ratio of (1: 1)-(3: 1). The plant stem cell extract consists of a ginseng stem cell extract and an angelica sinensis stem cell extract in a weight ratio of (3: 1)-(4: 1); through compatibility of the composite marine polysaccharide, the plant stem cell extract and other components, a repair-activation-protection closed loop is formed, and the limitation of a single component is broken through; by adopting processes such as low-temperature extraction and supercritical technology, the activity is retained to the maximum extent, the curative effect and safety of the preparation are improved, and an efficient treatment choice is provided for ovarian function decline.

The invention discloses an osmanthus fragrans extract for preventing premature ovarian failure and a preparation method and application thereof.The extract is prepared from osmanthus fragrans through microwave fixation, gradient temperature weak acid extraction, membrane separation and concentration, low-temperature drying and other pure physical processes, effective components can be prevented from being damaged, the process is stable, green and efficient, the active components are definite, and the preparation method is simple. Wherein the sum of the contents of the salidroside, the verbascoside and the ligustroside is not less than 20%. Animal experiments show that AMH, FSH and LH hormone levels in mice suffering from premature ovarian failure induced by cyclophosphamide can be remarkably improved, the ovarian function can be effectively improved, all index components including salidroside, verbascoside and ligustrum glycoside have a synergistic interaction effect, a safe and effective solution scheme derived from natural plants is provided for preventing premature ovarian failure, and the application prospect is wide. The method can be widely applied to preparation of various products.

The invention discloses a traditional Chinese medicine composition for improving related symptoms of ovarian insufficiency and application of the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicines. The method mainly comprises the following steps: selecting 6-15 parts by weight of artemisia apiacea, 6-12 parts by weight of scutellaria baicalensis, 9-18 parts by weight of morinda officinalis, 15-30 parts by weight of light wheat, 12-24 parts by weight of prepared rehmannia root, 9-18 parts by weight of lily, 3-9 parts by weight of prepared common monkshood daughter root and 15-30 parts by weight of calcined oyster shell, cleaning the raw material medicines to remove non-medicinal parts and impurities, properly crushing the calcined oyster shell to facilitate dissolution of effective components, and drying to obtain the traditional Chinese medicine composition. Soaking the cooked radix aconiti lateralis praeparata slices in saline water, and cooking to reduce the toxicity for later use; through scientific compatibility of traditional Chinese medicines such as artemisia apiacea, scutellaria baicalensis and morinda officinalis, and by following the treatment method of clearing the upper part and warming the lower part and traffic heart and kidney, comprehensive intervention is realized, so that vasomotor symptoms such as hectic fever, night sweat and the like can be remarkably improved, sleep disorders such as insomnia, upset and the like can be relieved, osteoporosis can be prevented and improved through the effects of tonifying kidney and strengthening bone, and meanwhile, the immune imbalance state can be regulated.

To provide a new diagnostic agent for ovarian function capable of diagnosing the functional change of ovary.SOLUTION: A diagnostic agent for ovarian function comprising a compound represented by the general formula (1-0) as an active ingredient. [In General Formula (1-0), R represents - O (CH2) n -, - O (CH2) nOC2H4 -, - CH2O (CH2) n -, or - CH2O (CH2) nOC2H4 -, n represents an integer of 1 to 5, and Q1 represents F or -. OCH3. ] SELECTED DRAWING: None

The invention discloses application of DFO and a composition thereof in functional recovery after ovarian transplantation. It is found for the first time that deferoxamine (DFO) can effectively improve the survival rate of follicles, increase the number of follicles and recover the functional structure of an ovary. In addition, it is found for the first time that the combination of DFO and vascular endothelial growth factor A (VEGF-A) has a synergistic effect on functional recovery after ovarian transplantation. The invention provides an effective drug and a drug combination strategy for functional recovery after ovarian transplantation, and has a wide application prospect in the technical field of development of repair drugs after ovarian transplantation.

The invention relates to a traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from thirty traditional Chinese medicine raw materials such as bull penis, cortex cinnamomi and alfalfa seeds and refined honey. The traditional Chinese medicine raw materials are crushed and mixed and then are prepared into honeyed boluses with the refined honey to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has the effects of warming and nourishing brain and kidney, and benefiting heart and replenishing essence, and can be used for effectively treating impotence, depression, spermatorrhea, premature ejaculation, body deficiency, emaciation, neurasthenia, premature ovarian insufficiency, ovarian reserve hypofunction, climacteric syndrome, infertility and / or infertility. The dracocephalum moldavica, the anchusa, the chicory and the hawthorn are further added, so that the efficacy of treating the impotence can be improved, and the effect of treating the hyperlipidemia is achieved.